Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 7, 2009

Vernalis and Servier Sign Second Cancer Drug Discovery Agreement

  • Vernalis and Servier signed a three-year collaboration to harness Vernalis’ fragment- and structure-based drug discovery platform for the identification of drug candidates against a new cancer target.

    The deal is in addition to the companies’ existing collaboration, signed in May 2007, focused on two oncology targets involved in protein-protein interactions. In October 2008, Vernalis received a €500,000 milestone from Servier for solving the novel crystal structure of one of the targets.



Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »